Advertisement
Screener

IMMUNITYBIO, INC. (IBRX) Graph

IBRX Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $51.24M; Cost of revenue $298.00K; Research and development (m); Selling, general and administrative (m).
  • 2026-03-31: Revenue $44.21M; Cost of revenue $238.00K; Research and development (m); Selling, general and administrative (m).
  • 2025-12-31: Revenue $38.28M*; Cost of revenue $382.00K*; Research and development (m); Selling, general and administrative (m).
  • 2025-09-30: Revenue $32.06M; Cost of revenue $177.00K; Research and development (m); Selling, general and administrative (m).

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

IBRX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Product AndService Other$568.00KProduct$50.67MRevenue$51.24MCost of revenue$298.00KOperating income-$61.70MOther income, net$242.00KPre-tax income-$230.39MIncome tax$0.00

Geography

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

IBRX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Europe$518.00KUS$50.72MRevenue$51.24MCost of revenue$298.00KOperating income-$61.70MOther income, net$242.00KPre-tax income-$230.39MIncome tax$0.00

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

IBRX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$51.24MRevenue$51.24MCost of revenue$298.00KOperating income-$61.70MOther income, net$242.00KPre-tax income-$230.39MIncome tax$0.00

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$51.24M$298.00K(m)(m)(m)$0.00-$230.38M
2026-03-31$44.21M$238.00K(m)(m)(m)$9.00K-$632.78M
2025-12-31$38.28M*$382.00K*(m)(m)(m)-$135.00K*-$62.05M*
2025-09-30$32.06M$177.00K(m)(m)(m)-$35.00K-$67.25M
2025-06-30$26.43M$136.00K(m)(m)(m)$269.00K-$92.56M
2025-03-31$16.52M$58.00K(m)(m)(m)-$234.00K-$129.65M
2024-12-31(m)(m)$35.22M*$41.73M*$76.95M*(m)(m)
2024-09-30$6.11M$0.00$50.44M$35.92M$86.36M$0.00-$85.73M
2024-06-30$1.05M$0.00$51.13M$49.25M$100.38M$0.00-$134.56M
2024-03-31$40.00K$0.00$53.35M$41.88M$95.24M$0.00-$134.11M
2023-09-30$82.00K$0.00$48.40M$31.82M$80.22M$0.00-$95.58M
2023-06-30$41.00K$0.00$53.17M$32.02M$85.19M$0.00-$137.88M
2023-03-31$360.00K(m)$79.26M$32.68M$111.94M$0.00-$116.34M
2022-09-30$118.00K(m)$71.61M$19.31M$90.92M$0.00-$110.94M
2022-06-30$35.00K(m)$63.08M$16.57M$79.66M$0.00-$94.59M
2022-03-31$14.00K(m)$55.38M$40.61M$95.99M$0.00-$102.83M
2021-09-30$66.00K(m)$49.28M$29.63M$78.90M$0.00-$87.63M
2021-06-30$339.00K(m)$53.80M$32.45M$86.25M$2.00K-$88.29M
2021-03-31$139.00K(m)$41.13M$45.27M$86.40M$6.00K-$79.61M
2020-12-31$21.00K(m)(m)(m)$30.91M(m)-$32.13M
2020-09-30$151.00K(m)$35.77M$19.60M$66.03M-$1.70M-$65.60M
2020-06-30$436.00K(m)$33.01M$18.35M$51.35M$45.00K-$51.44M
2020-03-31$165.00K(m)$27.37M$9.49M$36.87M$18.00K-$37.04M
2019-12-31$9.00K(m)(m)(m)$16.12M(m)-$15.64M
2019-09-30$12.00K(m)$12.05M$4.03M$16.08M$0.00-$15.58M
2019-06-30$17.00K(m)$13.13M$4.18M$17.31M$2.00K-$16.68M
2019-03-31$5.00K(m)$12.60M$5.74M$18.34M-$36.00K-$17.89M
2018-12-31$7.00K(m)(m)(m)$17.73M(m)-$17.34M
2018-09-30$31.00K(m)$14.56M$9.58M$24.14M-$128.00K-$23.64M
2018-06-30$4.00K(m)$14.69M$13.59M$28.28M-$123.00K-$27.73M
2018-03-31$5.00K(m)$13.99M$14.30M$28.29M-$124.00K-$27.52M
2017-12-31$12.00K(m)(m)(m)$25.41M(m)-$24.49M
2017-09-30$8.00K(m)$11.07M$13.38M$24.45M-$99.00K-$23.97M
2017-06-30$14.00K(m)$9.71M$14.13M$23.83M-$124.00K-$23.45M
2017-03-31$11.00K(m)$9.25M$16.23M$25.48M-$98.00K-$24.52M
2016-12-31$14.00K(m)(m)(m)$25.16M(m)-$24.24M
2016-09-30$12.00K(m)$8.36M$24.42M$32.79M-$52.00K-$31.90M
2016-06-30$12.00K(m)$6.39M$28.59M$34.98M-$228.00K-$34.00M
2016-03-31$6.00K(m)$4.96M$26.67M$31.62M-$143.00K-$30.68M
2015-12-31$15.00K(m)(m)$25.84M$29.94M(m)-$26.82M
2015-09-30$10.00K(m)$4.66M$41.81M$46.47M$0.00-$46.31M
2015-06-30$91.00K(m)$2.07M$128.41M$130.49M(m)-$130.89M
2015-03-31$120.00K(m)$603.00K$31.62M$32.22M$1.00K-$32.85M
2014-12-31$98.00K(m)(m)$1.83M$2.73M(m)-$2.75M
2014-09-30$133.00K(m)$328.00K$724.00K$1.05M(m)-$918.00K
2014-06-30$124.00K(m)$243.00K$1.08M$1.32M(m)-$1.42M
2014-03-31$286.00K(m)(m)$992.00K$1.11M(m)-$1.09M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$95.45M$536.00K(m)(m)(m)$9.00K-$863.16M
2025-06-30$42.94M$194.00K(m)(m)(m)$35.00K-$222.20M
2024-06-30$1.09M$0.00$104.48M$91.14M$195.62M$0.00-$268.67M
2023-06-30$401.00K$0.00$132.43M$64.69M$197.13M$0.00-$254.22M
2022-06-30$49.00K(m)$118.46M$57.18M$175.64M$0.00-$197.41M
2021-06-30$478.00K(m)$94.93M$77.72M$172.65M$8.00K-$167.90M
2020-06-30$601.00K(m)$60.38M$27.84M$88.22M$63.00K-$88.48M
2019-06-30$22.00K(m)$25.73M$9.92M$35.65M-$34.00K-$34.57M
2018-06-30$9.00K(m)$28.68M$27.89M$56.57M-$247.00K-$55.25M
2017-06-30$25.00K(m)$18.95M$30.36M$49.31M-$222.00K-$47.97M
2016-06-30$18.00K(m)$11.34M$55.26M$66.60M-$371.00K-$64.67M
2015-06-30$211.00K(m)$2.68M$160.03M$162.71M$1.00K-$163.74M
2014-06-30$410.00K(m)$363.00K$2.11M$2.48M$1.00K-$2.51M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30$75.00M$371.00K(m)(m)(m)$0.00-$289.45M
2024-09-30$7.19M$0.00$154.92M$127.05M$281.98M$0.00-$354.40M
2023-09-30$483.00K$0.00$180.83M$96.51M$277.34M$0.00-$349.80M
2022-09-30$167.00K(m)$190.07M$76.49M$266.56M$0.00-$308.35M
2021-09-30$544.00K(m)$144.21M$107.34M$251.55M$8.00K-$255.53M
2020-09-30$752.00K(m)$96.15M$47.44M$154.25M-$1.64M-$154.08M
2019-09-30$34.00K(m)$37.78M$13.95M$51.73M-$34.00K-$50.15M
2018-09-30$40.00K(m)$43.24M$37.47M$80.71M-$375.00K-$78.89M
2017-09-30$33.00K(m)$30.02M$43.74M$73.76M-$321.00K-$71.94M
2016-09-30$30.00K(m)$19.71M$79.68M$99.39M-$423.00K-$96.57M
2015-09-30$222.00K(m)$7.36M$201.81M$209.17M$1.00K-$210.05M
2014-09-30$543.00K(m)$691.00K$2.81M$3.51M$1.00K-$3.43M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$113.29M$753.00K(m)(m)(m)-$135.00K-$351.50M
2024-12-31$14.74M$0.00$190.14M$168.78M$358.93M$0.00-$413.60M
2023-12-31$622.00K$0.00$232.37M$129.62M$362.87M-$40.00K-$583.90M
2022-12-31$240.00K$0.00$248.15M$102.71M$351.54M$34.00K-$417.30M
2021-12-31$934.00K(m)$195.96M$135.26M$331.21M$9.00K-$349.80M
2020-12-31$605.00K(m)$139.51M$71.32M$221.49M-$1.85M-$221.85M
2019-12-31$2.20M(m)$112.00M$46.46M$158.45M-$105.00K-$157.78M
2018-12-31$47.00K(m)$55.72M$42.72M$98.44M-$503.00K-$96.23M
2017-12-31$45.00K(m)$42.04M$57.12M$99.17M-$493.00K-$96.42M
2016-12-31$44.00K(m)$29.15M$95.39M$124.54M-$572.00K-$120.81M
2015-12-31$236.00K(m)$11.43M$227.68M$239.11M-$301.00K-$236.88M
2014-12-31$641.00K(m)$1.59M$4.62M$6.22M$1.00K-$6.18M
2013-12-31$600.00K(m)$446.00K$2.42M(m)$1.00K-$2.05M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
REPLIGEN CORP (RGEN)United States$10.755B185.31
Immunovant, Inc. (IMVT)United States$7.028B-14.78
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
CRISPR Therapeutics AG (CRSP)$5.390B-11.68